CELL AND GENE THERAPY INSIGHTS

Market & Patient Access

August 2019
Market & Patient Access

Perspective

Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations

Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations

T Qiu, E Hanna, M Dabbous et al.
4 September 2019
Read
Breakthrough therapies, breakthrough economics in the era of cure

Breakthrough therapies, breakthrough economics in the era of cure

S Farnia, L Mostovoy, C Redding Flamm et al.
4 September 2019
Read
Genetic-based therapies: looking ahead to ensuring access to a cure for cystic fibrosis

Genetic-based therapies: looking ahead to ensuring access to a cure for cystic fibrosis

Lisa B Feng, Jacqueline V Erdo, Mary B Dwight
4 September 2019
Read
The diversity in regenerative medicines regulations in Europe, USA and Japan

The diversity in regenerative medicines regulations in Europe, USA and Japan

T Qiu, M Dabbous, L Chachoua et al.
4 September 2019
Read

Interview

Future trends in commercial cell and gene therapy: the investor’s perspective

Future trends in commercial cell and gene therapy: the investor’s perspective

Gregory Bonfiglio
4 September 2019
Read
Value demonstration and advanced therapies: the ARM perspective

Value demonstration and advanced therapies: the ARM perspective

Janet Lynch Lambert
4 September 2019
Read
Staying ahead of the curve: NICE’s approach to HTA of novel fields of biotech innovation

Staying ahead of the curve: NICE’s approach to HTA of novel fields of biotech innovation

Nick Crabb
4 September 2019
Read
Market access in the era of personalized cell & gene therapy

Market access in the era of personalized cell & gene therapy

Edward Abrahams
4 September 2019
Read
An outcomes-based, innovative reimbursement mechanism for curative medicines

An outcomes-based, innovative reimbursement mechanism for curative medicines

Omar Ali
3 September 2019
Read